TY - JOUR
T1 - How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide
AU - McCurdy, Shannon R.
AU - Luznik, Leo
N1 - Funding Information:
S.R.M. has received grant support from an American Cancer Society Institutional Research Grant. L.L. is supported by National Institutes of Health/National Cancer Institute grant 1P01CA225618.
Publisher Copyright:
© 2019 American Society of Hematology. All rights reserved.
PY - 2019/12/6
Y1 - 2019/12/6
N2 - HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.
AB - HLA-haploidentical hematopoietic stem cell transplantation is now one of the most commonly employed alternative donor techniques, with most centers applying T-cell-replete strategies such as that developed by the Baltimore group using high-dose posttransplant cyclophosphamide. HLA-haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide is associated with low rates of severe graft-versus-host disease and nonrelapse mortality and does not require graft manipulation or storage, which results in a low graft acquisition cost. Its remarkable safety when used with reduced-intensity conditioning has been demonstrated in patients up to 75 years old with outcomes similar to those of patients in their 50s. Several large, registry-based retrospective studies have confirmed the efficacy of HLA-haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide, achieving results comparable to those of HLA-matched hematopoietic stem cell transplantation. In this article, we describe our approach to this rapidly available and clinically simple platform and address some of the key clinical questions associated with its use.
UR - http://www.scopus.com/inward/record.url?scp=85076249389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076249389&partnerID=8YFLogxK
U2 - 10.1182/hematology.2019001323
DO - 10.1182/hematology.2019001323
M3 - Article
C2 - 31808908
AN - SCOPUS:85076249389
SN - 1520-4391
VL - 2019
SP - 513
EP - 521
JO - Hematology (United States)
JF - Hematology (United States)
IS - 1
ER -